M Johnston FRANZCR; L Guo MHSc; M Back FRANZCR, PgDip BSc (Hons); A Guminski FRACP; A Lee MBBS; C Hanna MBBS; D Veivers FRACS; A Wignall FRACS; T Eade FRANZCR.
Radiation Oncology—Original Article
Intensity-modulated radiotherapy using simultaneous-integrated boost for definitive treatment of locally advanced mucosal head and neck cancer: Outcomes from a single-institution series
Article first published online: 17 JAN 2013
© 2013 The Authors. Journal of Medical Imaging and Radiation Oncology © 2013 The Royal Australian and New Zealand College of Radiologists
Journal of Medical Imaging and Radiation Oncology
Volume 57, Issue 3, pages 356–363, June 2013
How to Cite
Johnston, M., Guo, L., Back, M., Guminski, A., Lee, A., Hanna, C., Veivers, D., Wignall, A. and Eade, T. (2013), Intensity-modulated radiotherapy using simultaneous-integrated boost for definitive treatment of locally advanced mucosal head and neck cancer: Outcomes from a single-institution series. Journal of Medical Imaging and Radiation Oncology, 57: 356–363. doi: 10.1111/1754-9485.12033
Conflicts of interest: None.
- Issue published online: 31 MAY 2013
- Article first published online: 17 JAN 2013
- Manuscript Accepted: 5 OCT 2012
- Manuscript Received: 15 MAY 2012
- head and neck;
- weekly cisplatin
The study aims to report outcomes for patients treated using intensity-modulated radiotherapy (IMRT) with simultaneous-integrated boost and weekly cisplatin for American Joint Committee on Cancer stage III/IV mucosal head and neck squamous cell carcinomas (HNSCCs).
Records for 67 patients treated definitively with IMRT for HNSCC were reviewed. By including only those treated with weekly cisplatin, 45 patients were eligible for analysis. Treatment outcomes, effect of patient, tumour and treatment characteristics on disease recurrence were analysed.
All patients completed IMRT to 7000 cGy in 35 fractions, with concurrent weekly cisplatin 40 mg/m2 (median 6 cycles). Median follow-up was 28 months for living patients. Two-year loco-regional recurrence-free, metastasis-free and overall survival were 85.4, 81.0 and 87.4%, respectively. Local recurrence occurred in three patients, and distant recurrence in eight patients.
Our results show efficacy of IMRT and weekly cisplatin in the treatment of stage III/IV HNSCC at our institution with respect to loco-regional control.